TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort

J. J. Bakhuizen*, F. B. Hogervorst, M. E. Velthuizen, M. W. Ruijs, K. van Engelen, T. A. van Os, J. J. Gille, M. Collee, A. M. van den Ouweland, C. J. van Asperen, C. M. Kets, A. R. Mensenkamp, E. M. Leter, M. J. Blok, M. M. de Jong, M. G. Ausems

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)273-280
Number of pages8
JournalFamilial Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Genetic testing
  • Li-Fraumeni syndrome
  • TP53
  • Breast cancer
  • Hereditary
  • LI-FRAUMENI SYNDROME
  • IMAGING SURVEILLANCE
  • CARRIERS
  • PREVALENCE
  • PHENOTYPE
  • GENOMICS
  • CRITERIA
  • RISKS
  • AGE

Cite this

Bakhuizen, J. J., Hogervorst, F. B., Velthuizen, M. E., Ruijs, M. W., van Engelen, K., van Os, T. A., Gille, J. J., Collee, M., van den Ouweland, A. M., van Asperen, C. J., Kets, C. M., Mensenkamp, A. R., Leter, E. M., Blok, M. J., de Jong, M. M., & Ausems, M. G. (2019). TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort. Familial Cancer, 18(2), 273-280. https://doi.org/10.1007/s10689-018-00118-0